NCT05900089View on ClinicalTrials.gov

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

June 1, 2026

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

SHR0302

SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions

Trial Locations (1)

Unknown

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT05900089 - Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma | Biotech Hunter | Biotech Hunter